MA43762A - Vaccin contre le rsv - Google Patents

Vaccin contre le rsv

Info

Publication number
MA43762A
MA43762A MA043762A MA43762A MA43762A MA 43762 A MA43762 A MA 43762A MA 043762 A MA043762 A MA 043762A MA 43762 A MA43762 A MA 43762A MA 43762 A MA43762 A MA 43762A
Authority
MA
Morocco
Prior art keywords
vaccine against
against rsv
rsv
vaccine
Prior art date
Application number
MA043762A
Other languages
English (en)
Inventor
Johannes Petrus Maria Langedijk
Janneke M Verhagen
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA43762A publication Critical patent/MA43762A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA043762A 2016-04-05 2017-04-04 Vaccin contre le rsv MA43762A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16163807 2016-04-05

Publications (1)

Publication Number Publication Date
MA43762A true MA43762A (fr) 2021-04-21

Family

ID=55661317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043762A MA43762A (fr) 2016-04-05 2017-04-04 Vaccin contre le rsv

Country Status (18)

Country Link
US (3) US10729757B2 (fr)
EP (1) EP3439694A1 (fr)
JP (2) JP7233928B2 (fr)
KR (3) KR102500970B1 (fr)
CN (1) CN109069612A (fr)
AU (1) AU2017248018A1 (fr)
BR (1) BR112018070323A2 (fr)
CA (1) CA3018139A1 (fr)
CL (1) CL2018002825A1 (fr)
EA (1) EA201892250A1 (fr)
IL (1) IL262109B2 (fr)
MA (1) MA43762A (fr)
MX (1) MX2018012095A (fr)
MY (1) MY193584A (fr)
PE (1) PE20190433A1 (fr)
PH (1) PH12018501912A1 (fr)
SG (1) SG11201807912SA (fr)
WO (1) WO2017174564A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102236497B1 (ko) * 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EP4011451A1 (fr) 2015-10-22 2022-06-15 ModernaTX, Inc. Vaccins contre le virus respiratoire
JP7233928B2 (ja) * 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
EP3595713A4 (fr) 2017-03-15 2021-01-13 ModernaTX, Inc. Vaccin contre le virus respiratoire syncytial
AU2018267971A1 (en) * 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) * 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
EP3746090A4 (fr) * 2018-01-29 2021-11-17 ModernaTX, Inc. Vaccins à base d'arn contre le vrs
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
WO2020229577A1 (fr) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
JP2022532742A (ja) * 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
CN112220921B (zh) 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
WO2022175477A1 (fr) * 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Antigènes fb de vrs de pré-fusion stabilisés
WO2022175479A1 (fr) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial
CN114277039B (zh) * 2021-10-25 2024-06-21 浙江君怡生物科技有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
WO2023198815A1 (fr) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Administration séquentielle d'adénovirus
WO2024041773A1 (fr) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Protéines rsv-f
WO2024069420A2 (fr) 2022-09-29 2024-04-04 Pfizer Inc. Compositions immunogènes comprenant un trimère de protéine f rsv
WO2024089634A1 (fr) 2022-10-27 2024-05-02 Pfizer Inc. Compositions immunogènes contre la grippe et le vrs
IL320459A (en) 2022-10-27 2025-06-01 Pfizer Rna molecules encoding rsv-f and vaccines containing them
JP2026500218A (ja) 2022-12-11 2026-01-06 ファイザー・インク インフルエンザおよびｒｓｖに対する免疫原性組成物
KR102806300B1 (ko) * 2023-01-13 2025-05-14 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
JP2026510670A (ja) * 2023-03-17 2026-04-10 成都威斯克生物医▲薬▼有限公司 呼吸器合胞体ウイルス感染症に対するワクチン
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
WO2025126071A1 (fr) 2023-12-14 2025-06-19 Pfizer Inc. Molécules d'arn
WO2025163460A2 (fr) 2024-01-30 2025-08-07 Pfizer Inc. Vaccins contre des maladies respiratoires
WO2025186719A1 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Compositions immunogènes et leurs utilisations
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
WO2026018181A1 (fr) 2024-07-17 2026-01-22 Pfizer Inc. Compositions immunogènes et leurs utilisations
WO2026038177A1 (fr) 2024-08-16 2026-02-19 Pfizer Inc. Compositions immunogènes et leurs utilisations

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
WO1998022588A2 (fr) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (fr) 1997-03-04 1998-09-11 Baxter International Inc. Lignees cellulaires de complementation de la region e1 d'un adenovirus
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
IL137510A0 (en) 1998-02-17 2001-07-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (fr) 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
EP1287159A4 (fr) 2000-05-08 2005-02-09 Davisco Foods Int Inc Traitement enzymatique des proteines de lactoserum permettant d'obtenir des peptides anti-hypertension, produits obtenus et traitement de l'hypertension chez les mammiferes
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469623C (fr) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition pour la conservation de virus
AR038153A1 (es) 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
EP1497440B1 (fr) 2002-04-25 2008-08-20 Crucell Holland B.V. Vecteurs adenoviraux stables et techniques de propagation de ces vecteurs
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CA2602944C (fr) 2005-04-11 2015-08-11 Crucell Holland B.V. Purification de virus faisant appel a une ultrafiltration
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
EP1998804B1 (fr) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprenant un adénovirus recombiné et un adjuvant
WO2008133663A2 (fr) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Compositions immunogènes à codons modifiés et procédés d'utilisation
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
CA2717142A1 (fr) 2008-02-29 2009-09-03 Tibotec Pharmaceuticals Procede d'identification d'inhibiteurs viraux utilisant une proteine de fusion de classe i
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
PL2370099T3 (pl) * 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
EP2445527A2 (fr) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccin
CA2768186A1 (fr) 2009-07-15 2011-01-20 Novartis Ag Compositions a base de proteine f du vrs et procedes de fabrication associes
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
CA2777116C (fr) 2009-10-15 2020-09-01 Crucell Holland B.V. Procede de purification d'adenovirus a partir de cultures a haute densite cellulaire
JP5393896B2 (ja) 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー アデノウイルス粒子の精製方法
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
BR112012031638B1 (pt) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
CA2835644C (fr) 2011-05-13 2021-06-15 Novartis Ag Antigenes de pre-fusion f du vrs
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
WO2014005643A1 (fr) 2012-07-05 2014-01-09 Okairos Ag Nouveaux régimes de primo-vaccination-rappel impliquant des polypeptides immunogènes codés par des polynucléotides
JP6210998B2 (ja) * 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
EP2970398B1 (fr) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Protéines f de rsv pré-fusion et leur utilisation
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US10196438B2 (en) 2013-04-15 2019-02-05 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
EA035846B1 (ru) 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US10125172B2 (en) 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
JP6013654B2 (ja) 2013-09-19 2016-10-25 クルセル ホランド ベー ヴェー 改良されたアデノウイルス製剤
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
US20220204567A1 (en) 2019-04-25 2022-06-30 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
JP2022532742A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
AU2021250630A1 (en) 2020-04-02 2022-10-20 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection

Also Published As

Publication number Publication date
JP7233928B2 (ja) 2023-03-07
US10729757B2 (en) 2020-08-04
KR20180132761A (ko) 2018-12-12
KR20220075436A (ko) 2022-06-08
US20200360506A1 (en) 2020-11-19
US20220288186A1 (en) 2022-09-15
BR112018070323A2 (pt) 2019-01-29
MX2018012095A (es) 2019-01-10
EA201892250A1 (ru) 2019-03-29
KR102500970B1 (ko) 2023-02-17
WO2017174564A1 (fr) 2017-10-12
PH12018501912A1 (en) 2019-06-17
US11338031B2 (en) 2022-05-24
SG11201807912SA (en) 2018-10-30
CA3018139A1 (fr) 2017-10-12
IL262109B2 (en) 2023-04-01
PE20190433A1 (es) 2019-03-21
AU2017248018A1 (en) 2018-09-27
JP2023029889A (ja) 2023-03-07
KR102491447B1 (ko) 2023-01-20
JP2019510497A (ja) 2019-04-18
IL262109B (en) 2022-12-01
US11801297B2 (en) 2023-10-31
CL2018002825A1 (es) 2018-11-16
EP3439694A1 (fr) 2019-02-13
CN109069612A (zh) 2018-12-21
KR102401247B1 (ko) 2022-05-25
IL262109A (en) 2018-11-29
MY193584A (en) 2022-10-19
KR20220018618A (ko) 2022-02-15
US20190125854A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
MA43762A (fr) Vaccin contre le rsv
IL288541A (en) vaccine against rsv
MA46766A (fr) Vaccin antigrippal
DK3393510T5 (da) Zikavirusvaccine
EP3595713A4 (fr) Vaccin contre le virus respiratoire syncytial
EP3364981A4 (fr) Vaccin contre le cytomégalovirus humain
EP3365008A4 (fr) Vaccin contre le virus respiratoire syncytial
EP3723320C0 (fr) Rach simple (srach)
PT4070788T (pt) Formulações farmacêuticas
GB201518684D0 (en) Vaccine
EP3004348A4 (fr) Vaccin contre le paludisme
DK3313436T3 (da) Multivalent pneumokok-konjugatvaccine
IL249823A0 (en) Meningococcus vaccines
MA46661A (fr) Formulations de vaccin glycoconjugué dirigé contre expec
EP3560512A4 (fr) Composition de vaccin contre le zona
FR3059559B1 (fr) Descendeur autobloquant
EP3405475A4 (fr) Vaccin contre les opioïdes de synthèse
GB201522132D0 (en) Vaccine
DK3280447T3 (da) Farmaceutiske formuleringer
EP3511016A4 (fr) Immunostimulant
DK3302016T3 (da) Ophængt plov
EP3562498A4 (fr) Vaccins contre la grippe
EP3527133A4 (fr) Audiomètre
EP3528843A4 (fr) Vaccins anti-opioïdes
DK3405212T3 (da) Cancervacciner